NEW VALUE AG: Change in valuation for portfolio company Sensimed SA

Baar (pta004/01.11.2018/18:30 UTC+1) After the successful registration and market approval of its product Triggerfish® as a medical device in the US, the same was also achieved in Japan. The cooperation with the Japanese industrial partner of Sensimed SA, who supported Sensimed SA in this process and also co-financed it, will now further be strengthened towards the commercialisation of the product in that country.

However, the major focus of the development of Sensimed SA remains currently directed on the extension of the medical studies and expanding the clinical data necessary for its global product commercialisation. Commercialisation of the product in the USA and Japan is presently focused on self-paying clients - the acceptance by insurance companies for reimbursements is a long and rather tedious process, requiring the abovementioned clinical confirmation data. The company has also developed a second product, which consists of a pressure sensor, integrated in a diagnostic lens.
In order to be able to cope with the slower-than-expected commercialisation while conducting these additional studies, Sensimed SA requires additional funding and has taken first steps to implement a further financing round.

As a first step the company has secured a bridge financing amounting to CHF1,3 million in autumn 2018. Despite its limited resources, New Value AG did participate in this round with CHF0,05 million. The additional equity financing has not been secured yet and is anticipated to be concluded during the first half of 2019. The impact of the terms and conditions of this forthcoming round on the valuation of this portfolio company of New Value cannot be determined yet.

However, the delayed commercialisation and the resulting additional financing demand of this portfolio company have led to a reviewed risk assessment by New Value AG. Based on this review, the Board of Directors of New Value AG has decided to adjust the valuation of Sensimed SA already now by CHF 1`500`000 in the half-year financial statements 2018. This adjustment impairs the NAV (Net Asset Value) of New Value AG by CHF 0,46 per share.

About New Value
New Value AG, which is listed on the SIX Swiss Exchange, invests directly in private companies with strong growth potential in Switzerland and neighbouring countries. New Value AG provides growth capital to promote innovative business models and supports the companies to market success. The companies included in the portfolio are mainly related to the cleantech and healthcare sectors.

(end)

Emitter:	NEW VALUE AG Zugerstrasse 8a 6340 Baar Switzerland
Contact Person:	Bernd Pfister
Phone:	+41 43 344 38 38
E-Mail:	pfister@newvalue.ch
Website:	www.newvalue.ch
ISIN(s):	CH0010819867 (Share)
Stock Exchange(s):	SIX Swiss Exchange